Skip to main content
Top
Published in: Journal of Hematology & Oncology 1/2018

Open Access 01-12-2018 | Correction

Correction to: miR-182-5p promotes hepatocellular carcinoma progression by repressing FOXO3a

Authors: Man-Qing Cao, A-Bin You, Xiao-Dong Zhu, Wei Zhang, Yuan-Yuan Zhang, Shi-Zhe Zhang, Kei-wei Zhang, Hao Cai, Wen-Kai Shi, Xiao-Long Li, Kang-Shuai Li, Dong-Mei Gao, De-Ning Ma, Bo-Gen Ye, Cheng-Hao Wang, Cheng-Dong Qin, Hui-Chan Sun, Ti Zhang, Zhao-You Tang

Published in: Journal of Hematology & Oncology | Issue 1/2018

Login to get access

Excerpt

The original article [1] contains an error in Fig. 5a whereby the Western blot bands representing CyclinD1 have mistakenly been duplicated over the Western blot bands intended to represent SGK.
Literature
Metadata
Title
Correction to: miR-182-5p promotes hepatocellular carcinoma progression by repressing FOXO3a
Authors
Man-Qing Cao
A-Bin You
Xiao-Dong Zhu
Wei Zhang
Yuan-Yuan Zhang
Shi-Zhe Zhang
Kei-wei Zhang
Hao Cai
Wen-Kai Shi
Xiao-Long Li
Kang-Shuai Li
Dong-Mei Gao
De-Ning Ma
Bo-Gen Ye
Cheng-Hao Wang
Cheng-Dong Qin
Hui-Chan Sun
Ti Zhang
Zhao-You Tang
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Journal of Hematology & Oncology / Issue 1/2018
Electronic ISSN: 1756-8722
DOI
https://doi.org/10.1186/s13045-018-0599-z

Other articles of this Issue 1/2018

Journal of Hematology & Oncology 1/2018 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine